|
CPEX continues to strengthen its intellectual property portfolio across the Company’s broader drug delivery business as
additional applications of CPE-215 are pursued. The technology, validated with the marketed product Testim, has broad applications to the universe of therapeutic peptides where a non-injectable formulation would provide
considerable market potential. Access to CPEX’s permeation enhancement technology with the key excipient, CPE-215, is currently
being offered to pharmaceutical and biotechnology companies whose products could potentially benefit from its permeation enhancement
properties – either as new product launches, as part of product lifecycle management or line-extension strategies. Our strategy includes
out-licensing of our CPE-215 permeation technology and in-licensing of drug targets.
If you would like to explore a possible partnership with CPEX Pharmaceuticals, please contact:
Lance Berman, M.D.
Senior Vice President and Chief Medical Officer
CPEX Pharmaceuticals, Inc.
2 Holland Way
Exeter, NH 03833
(603) 658-6100
lberman@cpexpharm.com |
